On February 3, 2026 The National Medical Products Administration (NMPA) reported it has approved the OncoMate Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended for use as a companion diagnostic to identify MSI-High (MSI-H) solid tumor patients for treatment with KEYTRUDA (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy. This is the first Promega companion diagnostic to receive NMPA approval.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This approval represents a step toward more personalized and effective cancer treatment in China," says Alok Sharma, Global Clinical Market Director at Promega. "We are proud to collaborate with pharmaceutical companies to deliver global solutions that expand access to innovative technologies and life-saving, effective therapies."
China continues to face one of the world’s highest cancer burdens, with solid tumors representing the vast majority of diagnoses nationwide. Despite advances in oncology care, most patients with advanced solid tumors ultimately progress after first-line therapy, creating a critical need for tools that can guide more effective alternative treatment strategies. The OncoMate MSI Detection Kit is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in solid tumors.
The approval was supported through a collaboration with Merck & Co., Inc., Rahway, NJ, USA, which markets KEYTRUDA. The collaboration reflects a shared commitment to improving access to diagnostics that guide therapeutic decision-making.
Promega MSI technology has received additional regulatory approvals in China, the European Union and the United States. OncoMate MSI Dx Analysis System was recently approved by the FDA as a companion diagnostic designed to identify patients with microsatellite stable (MSS) endometrial carcinoma who may benefit from treatment with KEYTRUDA plus LENVIMA (Lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.
OncoMate MSI Detection Kit will soon be available for purchase in China.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
(Press release, Promega, FEB 3, 2026, View Source [SID1234662444])